Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director · President and CEO | February 01, 2024 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FATE THERAPEUTICS INC
Report date February 01, 2024 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2034-01-31 | Direct | 500,000 |
Reported balance
After 2024-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2024, such that all of the shares shall be fully vested and exercisable on January 1, 2027, subject to the Reporting Person's continued service with the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,300 | $101.91 | $336,314.22 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,960 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $101.63 to $102.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 5,993 | $101.09 | $605,807.80 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,260 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $100.58 to $101.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,540 | $100.16 | $254,411.23 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,253 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $99.57 to $100.44 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2020. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,441 | Not disclosed Strike: $109.01 | Not disclosed |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · derivative · entry 17 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,441 Underlying: Common Stock · 16,441 shares Expires 2031-01-20 F16 · price: Not applicable. F15 · derivative.exercise_date: The shares subject to this option shall vest in 48 equal monthly installments beginning on February 1, 2021 such that this option is fully exercisable on January 1, 2025. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 23:23 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon stock | 43,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004957 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,793 F1 · security: Award of restricted stock units ("RSUs") that vests with respect to the 1/4th of the underlying shares on each of January 8, 2022, January 8, 2023, January 8, 2024, and January 8, 2025. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,300 | $109.65 | $252,204.20 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,562 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.19 to $110.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,772 | $110.76 | $307,021.18 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,862 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.19 to $111.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,515 | $111.62 | $392,330.24 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,634 F6 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 16,500 shares of Common Stock underlying RSUs granted to the reporting person on January 8, 2020. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.19 to $112.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,469 | $114.76 | $168,575.10 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,149 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 125,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.38 to $115.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 8,515 | $115.80 | $986,028.49 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,618 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 125,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.38 to $116.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 23,932 | $117.15 | $2,803,729.53 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,133 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 125,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.38 to $117.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 08, 2021 Filed Jan 13, 2021 01:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 26,904 | $117.60 | $3,163,883.50 |
DisclosureSEC source: 0001209191-21-003341 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,065 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 125,000 shares of Common Stock underlying RSUs granted to the reporting person on January 7, 2019. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $118.37 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · derivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,846 Underlying: Common Stock · 20,000 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F6 · price: Not applicable. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 100 | $93.44 | $9,344.00 |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,796 | $92.94 | $259,865.27 |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,069 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $92.43 to $93.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 13,936 | $91.77 | $1,278,913.69 |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,865 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $91.41 to $92.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 3,168 | $90.98 | $288,228.76 |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,801 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $90.41 to $91.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 20,000 | $6.62 | $132,400.00 |
DisclosureSEC source: 0001209191-20-064374 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 10,154 | Not disclosed Strike: $6.62 | Not disclosed |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · derivative · entry 15 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,846 Underlying: Common Stock · 10,154 shares Expires 2024-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F7 · price: Not applicable. F8 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 9,846 | Not disclosed Strike: $7.87 | Not disclosed |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · derivative · entry 14 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,846 shares Expires 2023-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F7 · price: Not applicable. F8 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · derivative · entry 13 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F7 · price: Not applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this options is fully exercisable on January 4, 2021. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 10,154 | $51.03 | $518,158.62 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 11 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 10,154 | $6.62 | $67,219.48 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 10 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 9,846 | $51.03 | $502,441.38 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 9 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 9,846 | $7.87 | $77,488.02 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 8 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 10,000 | $51.03 | $510,300.00 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 7 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.73 | Not disclosed |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · derivative · entry 12 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F7 · price: Not applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this options is fully exercisable on January 4, 2021. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 1,864 | $54.47 | $101,533.57 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F5 · price: Represents the weighted average sale price of the shares sold ranging from $54.35 to $54.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 10,846 | $53.98 | $585,505.04 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,833 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F4 · price: Represents the weighted average sale price of the shares sold ranging from $53.35 to $54.34 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 2,088 | $52.66 | $109,961.39 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,679 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F3 · price: Represents the weighted average sale price of the shares sold ranging from $52.15 to $53.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon stock | 15,202 | $51.61 | $784,523.53 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,767 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. F2 · price: Represents the weighted average sale price of the shares sold ranging from $51.14 to $52.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon stock | 30,000 | $2.73 | $81,900.00 |
DisclosureSEC source: 0001209191-20-058451 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0001209191-20-005968 · doc4.xml · derivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,600 Underlying: Common Stock · 25,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F4 · price: Not applicable. F3 · derivative.exercise_date: The shares subject to this option vested and became exercisable in 48 equal monthly installments beginning on January 1, 2016 such that this option was fully exercisable on December 1, 2019. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $25.45 | $636,302.50 |
DisclosureSEC source: 0001209191-20-005968 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F2 · price: Represents the weighted average sale price of the shares sold ranging from $25.06 to $25.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.70 | $67,500.00 |
DisclosureSEC source: 0001209191-20-005968 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 219,000 | Not disclosed Strike: $21.99 | Not disclosed |
DisclosureSEC source: 0001209191-20-003031 · doc4.xml · derivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,000 Underlying: Common Stock · 219,000 shares Expires 2030-01-08 F3 · price: Not applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 1, 2020 such that this option is fully exercisable on January 1, 2024. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003031 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,969 F1 · security: Award of restricted stock units that vests with respect to 1/4 of the underlying shares on each of January 8, 2021, January 8, 2022, January 8, 2023, and January 8, 2024. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · derivative · entry 6 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,600 Underlying: Common Stock · 25,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option vested and became exercisable in 48 equal monthly installments beginning on January 1, 2016 such that this option was fully exercisable on December 1, 2019. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $20.17 | $504,157.50 |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · nonDerivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F3 · price: Represents the weighted average sale price of the shares sold ranging from $20.00 to $20.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.70 | $67,500.00 |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · derivative · entry 5 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,600 Underlying: Common Stock · 25,000 shares Expires 2026-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option vested and became exercisable in 48 equal monthly installments beginning on January 1, 2016 such that this option was fully exercisable on December 1, 2019. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 25,000 | $20.08 | $501,897.50 |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,969 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. F2 · price: Represents the weighted average sale price of the shares sold ranging from $20.00 to $20.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 25,000 | $2.70 | $67,500.00 |
DisclosureSEC source: 0001209191-19-061760 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 19, 2019. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 20:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 21,017 | $14.44 | $303,458.16 |
DisclosureSEC source: 0001209191-19-053280 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,969 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of 43,125 shares of Common Stock underlying restricted stock units ("RSUs") granted to the reporting person on October 15, 2015. This sale was made pursuant to an irrevocable election on December 22, 2018 by the reporting person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.94 to $14.695 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: All remaining shares of Common Stock held by the reporting person are subject to the terms of a lock-up agreement with Jefferies LLC and Citigroup Global Markets Inc. (the "Representatives"), as representatives of the underwriters in the Company's public offering pursuant to a prospectus supplement dated September 11, 2019, pursuant to which the reporting person agreed, without the prior written consent of the Representatives, and subject to limited exceptions, not to sell, offer to sell, contract to sell or lend, effect any short sale, pledge, hypothecate or grant any security interest in, or otherwise transfer or dispose of, any shares of Common Stock, either directly or indirectly. Read SEC document |
| May 24, 2019 Filed May 28, 2019 20:01 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GiftCommon Stock | 105 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032958 · doc4.xml · nonDerivative · entry 1 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,986 Read SEC document |
| May 16, 2019 Filed May 17, 2019 22:27 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (right to buy) · Derivative | 14,335 | Not disclosed Strike: $1.63 | Not disclosed |
DisclosureSEC source: 0000899243-19-014037 · doc4.xml · derivative · entry 4 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,335 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F5 · price: Not applicable. F4 · derivative.exercise_date: The shares subject to this option became fully vested and exercisable on October 4, 2015. Read SEC document |
| May 16, 2019 Filed May 17, 2019 22:27 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 12,037 | $19.54 | $235,253.54 |
DisclosureSEC source: 0000899243-19-014037 · doc4.xml · nonDerivative · entry 3 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,881 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F3 · price: Represents the weighted average sale price of the shares sold ranging from $19.24 to $19.91 per share. The Reporting person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| May 16, 2019 Filed May 17, 2019 22:27 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 2,298 | $18.46 | $42,430.27 |
DisclosureSEC source: 0000899243-19-014037 · doc4.xml · nonDerivative · entry 2 Wolchko J Scott · CIK 0001586893 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,918 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2018. F2 · price: Represents the weighted average sale price of the shares sold ranging from $18.24 to $19.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.